The FDA has approved 2 new medications to treat 2 different hepatitis C virus (HCV) genotypes without coadministered interferon.
For patients with genotype 3 HCV infection, who comprise about 10% of the 2.7 million US residents infected with the virus, daclatasvir is approved to use in combination with sofosbuvir. In a trial involving 152 patients with chronic genotype 3 HCV infection, 98% of treatment-naive patients with no cirrhosis of the liver had sustained virologic response: no virus was detected in their blood 12 weeks after completing combination treatment (http://1.usa.gov/1VFlkaX).
Voelker R. Treatment for HCV Genotypes 3 and 4. JAMA. 2015;314(9):867. doi:10.1001/jama.2015.10492